# P&T Committee Meeting Minutes

**Subject:** Louisiana Department of Health and Hospitals  
Medicaid Pharmaceutical and Therapeutic Committee Meeting

**Location:** 628 North Fourth Street  
Baton Rouge, LA  
Bienville Building  
Room 118

**Date:** October 28, 2015

**Members Present:**  
- Brian Boulmay, MD  
- Jeff Deyo, MD  
- Rebecca Gee, MD  
- Martha Harris, PharmD  
- Ed Mader, MD  
- Marty R. McKay, RPh  
- Fred Mills, RPh  
- Ben Orlando  
- Roger Pope  
- Suki Subbiah, MD  
- Neil Wolfson, MD

**DHH Pharmacy Program Staff Present:**  
- Melwyn Wendt, RPh  
- Germaine Becks-Moody, PhD, BHSF Program Manager  
- Sue Fontenot, RPh  
- Paul Knecht, RPh  
- Kim Sullivan  
- Mary Wolfe

**Contractors Present:**  
- Nina Bandali, PharmD, Magellan Medicaid Administration  
- Julie Pritchard, PharmD, Magellan Medicaid Administration  
- Jennifer Picket, Certified Court Reporter

**Others Present:** Presenters are listed in the minutes and sign in sheets and others in attendance from DHH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.

## Call to Order

Marty R. McKay, Chairman, called the meeting to order at 9:16 a.m.
Parliamentary Business

A. Introduction of Members/Roll Call. Committee members and staff introduce themselves.

B. Approval of Minutes. Mr. McKay asked for a motion to approve the minutes from October 29, 2014. There were no objections to approving the minutes. Mr. McKay asked for a motion to reorder the agenda as necessary due to the large agenda. Dr. Orlando offered a motion to reorder the agenda. Dr. Wolfson seconded the motion which passed. Mr. McKay announced that one of the changes being made is that a roll call vote will not be necessary each time. If there is opposition then a roll call vote will take place.

Ethics Reminder

Code of Ethics. Ms. Sullivan went over the code of ethics. Members are bound by the governmental code of ethics. She suggested for all to go to the Board’s website, http://www.ethics.state.la.us, to access a Power Point presentation that all state employees have to do. If anyone has personal ethical questions, please contact Kim Sullivan at Kimberly.sullivan@la.gov.

New Business

A. Therapeutic Class Reviews of Spring Drug Classes/Drug Manufacturer Testimony

In accordance with state law and the P&T Committee’s bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee’s review.

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Representing</th>
<th>Drug/Issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gia Tyson</td>
<td>Ochsner Medical Center.</td>
<td>Harvoni</td>
</tr>
<tr>
<td>Chester Grobowski</td>
<td>Gilead Sciences</td>
<td>Harvoni</td>
</tr>
</tbody>
</table>

Hepatitis C Agents

Dr. Wolfson makes the motion to accept. Dr. Deyo seconds the motion. After discussion, there was no objection to the motion.

Committee recommendations for the PDL are:

- Daklinza
- Pegasys Proclick
- Pegasys Syringe
- Pegasys Vial
- Ribavirin tablet
- Technivie
- Viekira Pak

B. Therapeutic Class Reviews of Fall Drug Classes/Drug Manufacturer Testimony
In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Representing</th>
<th>Drug/Issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinn Cho Dunn</td>
<td>Abbvie</td>
<td>Duopa</td>
</tr>
<tr>
<td>Nicole Magee</td>
<td>National Alliance on Mental Illness of Louisiana</td>
<td>Unrestricted, open access for medications for mental illness</td>
</tr>
<tr>
<td>Camilla Pecos</td>
<td>Otsuka</td>
<td>Rexulti, Abilify Maintena</td>
</tr>
<tr>
<td>Mike Donsy</td>
<td>Boehringer Ingelheim</td>
<td>Spiriva Respimat, Stiolto Respimat</td>
</tr>
<tr>
<td>Kenyatta Peoples</td>
<td>Novartis Pharmaceuticals</td>
<td>Cosentyx</td>
</tr>
<tr>
<td>Shelly Balm</td>
<td>Celgene Corp.</td>
<td>Otezla</td>
</tr>
<tr>
<td>Ann McMann Wicker</td>
<td>Pfizer</td>
<td>Xeljanz, Lyrica</td>
</tr>
</tbody>
</table>

Alzheimer's Agents

Dr. Orlando makes the motion to accept. Dr. Mader seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Donepezil ODT
- Donepezil tablet
- Exelon
- Memantine tablet, tablet dose pack

Antidepressants, Other

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- All Forms of Generic Bupropion and Bupropion SR
- Mirtazapine and ODT
- Pristiq
- Trazodone
- Venlafaxine
- Venlafaxine ER capsule
Antidepressants, SSRI

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Citalopram tab and soln
- Escitalopram tab
- Fluoxetine caps, soln
- Fluvoxamine
- Paroxetine tab
- Sertraline tab and soln

Antihistamines, Minimally Sedating

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Cetirizine
- Levocetirizine
- Loratadine

Antihypertensives, Sympatholytics

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Catapres-TTS patch
- Clonidine generic
- Guanfacine
- Methyldopa
- Methyldopa/Hydrochlorothiazide oral

Antihyperuricemics

Dr. Wolfson makes the motion to accept. Dr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Allopurinol
- Probenecid
• Probenecid combination with Colchicine

**Antiparkinson’s**

Dr. Orlando makes the motion to accept. Dr. Mader seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Amantadine  
• Benztropine  
• Carbidopa/levodopa  
• Carbidopa/levodopa ER  
• Carbidopa/levodopa/entacapone  
• Pramipexole  
• Ropinirole  
• Selegiline tab/cap  
• Trihexyphenidyl tab/elixir

**Antipsoriatics, Oral**

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Soriatane

**Antipsoriatics, Topical**

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Calcipotriene cream, ointment, and solution

**Antipsychotics**

Dr. Gee makes the motion to accept. Dr. Mader seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Amitriptyline/perphenazine oral  
• Chlorpromazine oral  
• Clozapine oral  
• Olanzapine tab/ODT  
• Orap  
• Perphenazine oral
- Fluphenazine tab/inj
- Geodon IM
- Haloperidol lactate conc/oral/inj
- Haloperidol decanoate inj
- Invega Sustenna
- Invega Trinza
- Latuda oral
- Loxapine oral
- Quetiapine oral
- Risperdal Consta inj
- Risperidone tab/soln
- Seroquel XR
- Thioridazine oral
- Thiothixene oral
- Trifluoperazine oral
- Ziprasidone cap

**Anxiolytics**

Dr. Orlando makes the motion to accept. Dr. Mader seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- buspirone
- lorazepam

**Bile Salts**

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Ursodiol tablet

**Bronchodilators**

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Albuterol nebulizer solutions – all strengths
- Albuterol tab/syrup
- Foradil
- ProAir HFA
- Proventil HFA
- Serevent
- Terbutaline oral
COPD Agents

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Atrovent HFA
- Combivent Respimat
- Ipratropium/Albuterol combination nebulizer
- Ipratropium nebulizer
- Spiriva

Cytokine and CAM Antagonists

Senator Mills makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Enbrel
- Humira

Emollients

Dr. Orlando makes the motion to accept. Representative Pope seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Ammonium lactate cream/lotion
- Lactic Acid cream/lotion

Erythropoiesis Stimulating Proteins

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Aranesp
- Procrit

Glucocorticoids, Inhaled

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

---
• Advair Diskus
• Asmanex
• Dulera
• Pulmicort Respules 0.25 mg, 0.5 mg, 1 mg
• Qvar
• Symbicort

**Histamine II Receptor Blockers**

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Famotidine tabs
• Ranitidine syrup and tabs

**Immunomodulators, Atopic Dermatitis**

Dr. Orlando makes the motion to accept. Dr. Harris seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Elidel

**Immunomodulators, Topical**

Dr. Orlando makes the motion to accept. Dr. Harris seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Aldara

**Intranasal Rhinitis Agents**

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Fluticasone
• Ipratropium nasal
• Nasonex
• Patanase
Leukotriene Modifiers

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:
- Montelukast tab/chew tab

Neuropathic Pain

Dr. Mader makes the motion to accept. Dr. Orlando seconds the motion. Dr. Wolfson initiated discussion on Lyrica. Roll call was taken and the original motion passed.

Committee recommendations for the PDL are:
- Duloxetine
- Gabapentin caps
- Lidoderm
- Neurontin solution

NSAIDS

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:
- Diclofenac sodium and SR
- Ibuprofen tab and susp
- Indocin susp
- Indomethacin caps
- Ketoprofen
- Keltorolac
- Meloxicam tab and susp
- Nabumetone
- Naproxen tab, susp and naproxen EC
- Sulindac

Ophthalmic Antibiotics/Steroids Combination

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:
- Neomycin/polymyxin B/Dexamethasone combination
- Sulfacetamide/Prednisolone combination
- TobraDex ointment and suspension
Ophthalmic Antibiotics

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Bacitracin/polymyxin B sulfate oint
- Bleph-10
- Ciprofloxacin soln
- Erythromycin
- Garamycin
- Gentamicin drops/ointment
- Ilotycin
- Moxeza
- Neomycin/polymyxin/gramicidin
- Ofloxacin
- Polymyxin/trimethoprim
- Sulfacetamide soln
- Tobramycin
- Vigamox

Ophthalmics for Allergic Conjunctivitis

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Alrex
- Cromolyn
- Pataday
- Pazeo

Ophthalmic Anti-inflammatories

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Dexamethasone
- Diclofenac
- Durezol
- Fluorometholone
- Flurbiprofen
- Ketorolac and LS

Ophthalmics, Glaucoma Agents

Dr. Wolfson makes the motion to accept. Dr. Orlando seconds the motion. There was no objection to the motion.
Committee recommendations for the PDL are:

- Alphagan P 0.15%
- Brimonidine
- Carteolol
- Combigan
- Dorzolamide and Dorzolamide/timolol
- Latanoprost 2.5 mL
- Levobunolol
- Metipranolol
- Pilocarpine
- Simbrinza
- Timolol
- Travatan-Z

Otic Anti-infectives & Anesthetics

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Acetic Acid
- Acetic Acid/Aluminum
- Antipyrine/Benzocaine combination

Otic Antibiotics

Dr. Harris makes the motion to accept. Dr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Ciprodex
- Neomycin/Polymyxin/Hydrocortisone solution suspension

Sedative Hypnotics

Dr. Orlando makes the motion to accept. Dr. Mader seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Temazepam
- Triazolam
- Zolpidem

Smoking Cessation

Dr. Orlando makes the motion to accept. Senator Mills seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:
- Bupropion SR
- Chantix and Chantix Dose Pack
- Nicotine gum, lozenge, patch

**Steroids Topical, High Potency**

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Betamethasone dipropionate/prop gly cream
- Betamethasone valerate cream/lotion/ointment
- Fluocinonide cream/soln/emollient
- Triamcinolone acetonide cream/lotion/ointment

**Steroids Topical, Low Potency**

Dr. Orlando makes the motion to accept. Dr. Harris seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Alclocetasone dipropionate cream/ointment
- Hydrocortisone cream/gel/lotion/ointment
- Hydrocortisone/Mineral Oil/Petrolatum combination

**Steroids Topical, Medium Potency**

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Fluticasone propionate ointment/cream
- Hydrocortisone Butyrate soln
- Mometasone furoate soln/cream/ointment
- Prednicarbate cream

**Steroids Topical, Very High Potency**

Dr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Clobetasol emollient
• Clobetasol propionate cream, gel, oint, soln

Stimulants and Related Agents

Dr. Wolfson makes the motion to accept. Dr. Deyo seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

• Adderall XR
• Amphetamine Salt Combo Immediate Release
• Dexamfetamine
• Dextroamphetamine
• Focalin
• Focalin XR
• Guanfacine ER
• Metadate CD
• Methylphenidate IR and ER (generic for Concerta)
• ProCentra
• Quillivant XR
• Strattera
• Vyvanse
II. Single Drugs

The new drug reviews or single drug reviews are on products that have come to the market since the last review of the class or products that were not reviewed during the May meeting due to a lack of a quorum.

In accordance with state law and the P&T Committee’s bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee’s review.

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Representing</th>
<th>Drug/Issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ann McMann Wicker</td>
<td>Pfizer</td>
<td>Embeda</td>
</tr>
<tr>
<td>Lois Peters</td>
<td>Sanofi</td>
<td>Praluent</td>
</tr>
<tr>
<td>Karen Dubusk</td>
<td>Biogen Idec</td>
<td>Plerigy</td>
</tr>
<tr>
<td>Julie Shirley</td>
<td>Genzyme</td>
<td>Lemtrada</td>
</tr>
<tr>
<td>Margaret Campbell</td>
<td>Novartis</td>
<td>Entresto</td>
</tr>
</tbody>
</table>

**NOTE:** Names of speakers who were present and yielded their time back were not captured.

The single drugs were reviewed and a recommendation was made. P&T Committee recommendations follow:

**Analgesics Narcotics, Long**

Mr. McKay stated that the single drug reviews will be voted on as a group unless someone has an objection. Senator Mills makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion. Ms. Sullivan expressed her approval to vote in globo.

*Committee recommendations for the PDL are:*

- Non-prefer Embeda
- Non-prefer fentanyl 37.5, 62.5, 87.5 mg transderm
- Non-prefer hydromorphone ER (AG)
- Non-prefer Hysingla ER
- Non-prefer methadone concentrate, sol tabs, solution, and tablets
- Non-prefer oxycodone ER (AG)
- Non-prefer tramadol ER (generic Conzip)

**Lipotropics, Other**

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. There was no objection to the motion.
Committee recommendations for the PDL are:

- Non-prefer omega-3 acid ethyl esters
- Non-prefer Praluent
- Non-prefer Repatha

Multiple Sclerosis Agents

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer glatiramer (Glatopa)
- Non-prefer Lemtrada
- Non-prefer Plegridy

Antibiotics, Inhaled

Dr. Orlando makes the motion to accept, Dr. Harris seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Prefer Kitabis Pak

Anticoagulants

Dr. Orlando makes the motion to accept Savaysa as non-preferred, Dr. Harris seconds the motion. There was no objection to the motion. Dr. Orlando makes the motion to accept Xarelto Dose Pack as preferred, Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Savaysa
- Prefer Xarelto Dose Pack

Growth Hormone

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:
• Non-prefer Zomacton

**Hypoglycemics, Incretin Mimetics/Enhancers**

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Glyxambi

• Non-prefer Trulicity

**Hypoglycemics, Insulin and Related Agents**

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Afrezza

• Non-prefer Toujeo Solostar

**Hypoglycemics, SGLT2**

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Synjardy

• Non-prefer Xigduo XR

**Opiate Dependence Treatments**

Dr. Orlando makes the motion to accept, Dr. Harris seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Bunavail

**Angiotensin Modulators**

Dr. Orlando makes the motion to accept, Dr. Boulney seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Entresto
• Prefer valsartan

**PAH Agents, Oral and Inhaled**

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Revatio suspension

**Antifungals, Oral**

Dr. Orlando makes the motion to accept, Senator Mills seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Cresemba

**Proton Pump Inhibitors**

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. There was no objection to the motion.

• *Committee recommendations for the PDL are:*

  • Non-prefer esomeprazole capsules

**Antimigraine Agents, Triptans**

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer almotriptan

  • Non-prefer Zecuity

**Lincosamides/Oxazolidinones/Streptogramins**

Dr. Orlando makes the motion to accept, Representative Pope seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer linezolid iv and oral

**Phosphate Binders**

Senator Mills makes the motion to accept, Dr. Orlando seconds the motion. There was no objection to the motion.
Committee recommendations for the PDL are:

- Non-prefer Auryxia
- Non-prefer Fosrenol powder pack
- Non-prefer sevelamer carbonate

Cephalosporins and Related Antibiotics

Dr. Orlando makes the motion to accept, Dr. Deyo seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer cefixime suspension

Analgesics, Narcotics Short

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Lazanda
- Non-prefer Reprexain

Angiotensin Modulator Combinations

A motion was made to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer amlodipine/valsartan
- Non-prefer amlodipine/valsartan/hctz
- Non-prefer trandolapril/verapamil

Antibiotics, Vaginal

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Nuvessa

Antiemetic/Antivertigo Agents

A motion was made to accept and seconded. There was no objection to the motion.
Committee recommendations for the PDL are:

- Non-prefer Akynzeo
- Non-prefer metoclopramide ODT

Antifungals, Topical

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Bensal HP
- Non-prefer Extina
- Non-prefer Kerydin
- Non-prefer naftifine cream
- Non-prefer Penlac

Beta Blockers

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer Inderal XL
- Non-prefer Sotylize

Bone Resorption Suppression and Related Agents

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer raloxifene
- Non-prefer risedronate

Calcium Channel Blockers

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Non-prefer diltiazem LA
Fluoroquinolones, Oral

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:
  - Non-prefer ciprofloxacin suspension

Hypoglycemics, TZD

Dr. Wolfson makes the motion to accept, Dr. Harris seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:
  - Non-prefer pioglitazone/glimepiride (AG)

Platelet Aggregation Inhibitors

Dr. Wolfson makes the motion to accept, Dr. Orlando seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:
  - Non-prefer aspirin/dipyridamole

Tetracyclines

Senator Mills makes the motion to accept, Dr. Orlando seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:
  - Prefer doxycycline hyclate capsule (AG)

Ulcerative Colitis Agents

Dr. Orlando makes the motion to accept, Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:
  - Non-prefer Uceris oral and rectal

Therapy classes to be reviewed for the May 2016 meeting will be posted on the DHH Medicaid Pharmacy and Therapeutics Committee page as “Agenda.”

Managed Care Update

A. Angela Marshall from DHH provides a Managed Care update. Ms. Marshall announced that Behavioral Health will be integrated to Bayou Health with no change to the pharmacy
benefit. Open enrollment is currently going on. It started August 24th and will run through November 6th. After November 6th, members will be auto-assigned into a Bayou Health plan if not selected. Everyone will be enrolled in Bayou Health for specialized behavioral health services including dual eligibles. Some groups can opt out of their acute care services including the prison population and some of the waiver populations. These individuals will have the option to receive their acute care services through Legacy Medicaid, but they’ll be required to receive their specialized behavioral health services through Bayou Health. Specialized behavioral health providers who were once enrolled with Magellan, will now have to sign contracts and enroll with the five Bayou Health plans.

B. Melwyn Wendt from DHH provides report. Ms. Wendt called the Committee members’ attention to the packet they received with the Prior Authorization (PA) PDL implementation schedule. Changes made today will be implemented on January 1, 2016. She also pointed out that Magellan has created a preferred drug list program overview and results. Ms. Wendt stated that we will try to do a synopsis at the beginning of the next meeting.

Senator Mills inquired if projected savings to actual savings can be provided with the Magellan cost sheets. Ensuing discussion included comments from Ms. Pritchard that numerous factors can impact projections such as new market entrants, new generics, shortages. She further explained that Magellan does provide the State monthly market shift reports and quarterly reports which include cost avoidance and cost savings. Dr. Gee and several other members stressed accountability and stated that these reports are not being provided to the Committee. Ms. Wendt stated that she will further discuss with Dr. Becks-Moody and Magellan to provide additional information to the Committee with specific qualifiers. Dr. Bandali commented that the annual report was provided by Dr. Becks-Moody to the Committee which also contains this information. Ms. Wendt confirmed her understanding that the Committee is requesting a report in a different format. Senator Mills explained what they are trying to do more and more of in the Senate and the House is projecting, what was the spend, where were mistakes made or where are we doing better. Further discussion occurred on the difficulty of projecting due to the movement of the population. Ms. Wendt stated that 90% or more is in managed care and most of it will be stabilized for now. In February of 2015, 400,000 to 450,000 people moved into managed care.

Senator Mills further questioned whether the cost of per member per month for fee-for-service versus the five health plans was being analyzed. Ms. Wendt did not believe that much was being done by the actuary on this type of a comparison since it would not compare apples to apples, but she agreed to ask.

Dr. Dunham stated that whereas Vivitrol is an opiate antagonist, its’ indicated use is really in alcohol treatment. She considered it to be tremendously valuable in recovering from alcohol dependence because it’s a long-acting monthly injectable. She felt it was misclassified under the Opiate Dependence treatments and should be reconsidered since it
is an important drug for alcohol remission. Dr. Bandali responded that Magellan will take this back and evaluate it.

Proposed Therapeutic Classes to be Reviewed at Next Meeting

Therapy classes to be reviewed for the May 2016 meeting will be posted on the DHH Medicaid Pharmacy and Therapeutics Committee page as “Agenda.”

Next Meeting Date

The next committee meeting is scheduled for May 4, 2016.

Adjournment

The meeting adjourned at 12:48 p.m.

Marty McKay, Chairman